These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12634651)
1. Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis. Cusick W; Buchanan P; Hallahan TW; Krantz DA; Larsen JW; Macri JN Am J Obstet Gynecol; 2003 Mar; 188(3):745-51. PubMed ID: 12634651 [TBL] [Abstract][Full Text] [Related]
2. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis. Caughey AB; Kuppermann M; Norton ME; Washington AE Am J Obstet Gynecol; 2002 Nov; 187(5):1239-45. PubMed ID: 12439512 [TBL] [Abstract][Full Text] [Related]
3. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness model for first-trimester versus second-trimester ultrasound screening for Down syndrome. Kott B; Dubinsky TJ J Am Coll Radiol; 2004 Jun; 1(6):415-21. PubMed ID: 17411619 [TBL] [Abstract][Full Text] [Related]
7. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialard F; Giudicelli Y; Ville Y Am J Obstet Gynecol; 2006 Nov; 195(5):1379-87. PubMed ID: 16723105 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic. Dhaifalah I; Májek O Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640 [TBL] [Abstract][Full Text] [Related]
9. [Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population]. Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialat F; Giudicelli Y; Ville Y Gynecol Obstet Fertil; 2007 Apr; 35(4):303-11. PubMed ID: 17350315 [TBL] [Abstract][Full Text] [Related]
10. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
11. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. Gilbert RE; Augood C; Gupta R; Ades AE; Logan S; Sculpher M; van Der Meulen JH BMJ; 2001 Aug; 323(7310):423-5. PubMed ID: 11520837 [TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of the Hong Kong Hospital Authority universal Down syndrome screening programme. Sahota DS; Leung WC; Chan WP; To WW; Lau ET; Leung TY Hong Kong Med J; 2013 Apr; 19(2):101-8. PubMed ID: 23535668 [TBL] [Abstract][Full Text] [Related]
13. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220 [TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Muller F; Benattar C; Audibert F; Roussel N; Dreux S; Cuckle H Prenat Diagn; 2003 Oct; 23(10):833-6. PubMed ID: 14558029 [TBL] [Abstract][Full Text] [Related]
16. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Biggio JR; Morris TC; Owen J; Stringer JS Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005 [TBL] [Abstract][Full Text] [Related]
17. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Christiansen M; Olesen Larsen S Prenat Diagn; 2002 Jun; 22(6):482-6. PubMed ID: 12116307 [TBL] [Abstract][Full Text] [Related]
18. Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study. Rozenberg P; Malagrida L; Cuckle H; Durand-Zaleski I; Nisand I; Audibert F; Benattar C; Tribalat S; Cartron M; Lemarié P; Stoessel J; Capolagui P; Jansé-Marec J; Barbier D; Allouch C; Perdu M; Roberto A; Lahna Z; Giudicelli Y; Ville Y Hum Reprod; 2002 Apr; 17(4):1093-8. PubMed ID: 11925411 [TBL] [Abstract][Full Text] [Related]
19. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Hackshaw AK; Wald NJ Prenat Diagn; 2001 Sep; 21(9):741-6. PubMed ID: 11559910 [TBL] [Abstract][Full Text] [Related]